BioMarin Pharma (BMRN) Tops Q1 EPS by 39c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $57.29 -2.09%
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
LTBR, AES, SYRS, More
Financial Fact:
Research and development: 160.83M
Today's EPS Names:
LTBR, AES, SYRS, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q1 EPS of $0.71, $0.39 better than the analyst estimate of $0.32. Revenue for the quarter came in at $649 million versus the consensus estimate of $649.27 million.
GUIDANCE:
BioMarin Pharma sees FY2024 EPS of $2.75-$2.95, versus the consensus of $2.75. BioMarin Pharma sees FY2024 revenue of $2.7-2.8 billion, versus the consensus of $2.76 billion.
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharma (BMRN) Tops Q3 EPS by 11c
- Celanese Corp. (CE) Tops Q3 EPS by 9c; offers guidance
- SBA Communications (SBAC) Tops Q3 EPS by 10c; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
